Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lung cancer in renal transplant recipients: A case-control study.
Rousseau-Gazaniol C, Fraboulet S, Couderc LJ, Kreis H, Borie R, Tricot L, Anglicheau D, Martinez F, Doubre H, Bonnette P, Mellot F, Massiani MA, Pelle G, Sage E, Moisson P, Delahousse M, Zemoura L, Chapelier A, Hamid AM, Puyo P, Longchampt E, Legendre C, Friard S, Catherinot E. Rousseau-Gazaniol C, et al. Among authors: massiani ma. Lung Cancer. 2017 Sep;111:96-100. doi: 10.1016/j.lungcan.2017.07.011. Epub 2017 Jul 11. Lung Cancer. 2017. PMID: 28838407
Lung cancer in patients with HIV Infection and review of the literature.
Spano JP, Massiani MA, Bentata M, Rixe O, Friard S, Bossi P, Rouges F, Katlama C, Breau JL, Morere JF, Khayat D, Couderc LJ. Spano JP, et al. Among authors: massiani ma. Med Oncol. 2004;21(2):109-15. doi: 10.1385/MO:21:2:109. Med Oncol. 2004. PMID: 15299182 Review.
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M, Assié JB, Monnet I, Massiani MA, Tabeze L, Friard S, Fraboulet S, Métivier AC, Chouaïd C, Zemoura L, Longchampt E, Callens C, Melaabi S, Couderc LJ, Doubre H. Mayenga M, et al. Among authors: massiani ma. Lung Cancer. 2020 Dec;150:21-25. doi: 10.1016/j.lungcan.2020.09.008. Epub 2020 Sep 16. Lung Cancer. 2020. PMID: 33045465
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Seban RD, Assié JB, Giroux-Leprieur E, Massiani MA, Bonardel G, Chouaid C, Deleval N, Richard C, Mezquita L, Girard N, Champion L. Seban RD, et al. Among authors: massiani ma. Lung Cancer. 2021 Sep;159:45-55. doi: 10.1016/j.lungcan.2021.06.024. Epub 2021 Jul 20. Lung Cancer. 2021. PMID: 34311344
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy.
Chelabi S, Mignard X, Leroy K, Monnet I, Brosseau S, Theou-Anton N, Massiani MA, Friard S, Duchemann B, Fabre E, Giroux-Leprieur E, Cadranel J, Wislez M. Chelabi S, et al. Among authors: massiani ma. Cancers (Basel). 2021 Oct 13;13(20):5132. doi: 10.3390/cancers13205132. Cancers (Basel). 2021. PMID: 34680280 Free PMC article.
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Bilger G, Girard N, Doubre H, Levra MG, Giroux-Leprieur E, Giraud F, Decroisette C, Carton M, Massiani MA. Bilger G, et al. Among authors: massiani ma. Cancer Immunol Immunother. 2022 Jul;71(7):1719-1731. doi: 10.1007/s00262-021-03114-z. Epub 2021 Nov 25. Cancer Immunol Immunother. 2022. PMID: 34821950 Free PMC article. Clinical Trial.
Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancer.
Basse C, Ancel J, Massiani MA, Bonté PE, Beaulaton C, Beaucaire-Danel S, Milder M, Cao K, Daniel C, Du Rusquec P, Sablin MP, Kirova Y, Sage E, Beddok A, Girard N. Basse C, et al. Among authors: massiani ma. Lung Cancer. 2023 Aug;182:107295. doi: 10.1016/j.lungcan.2023.107295. Epub 2023 Jul 11. Lung Cancer. 2023. PMID: 37442059
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators. Le Tourneau C, et al. Among authors: massiani ma. Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3. Lancet Oncol. 2015. PMID: 26342236 Clinical Trial.
30 results